Company profile: Strongbridge Biopharma
1.1 - Company Overview
Company description
- Provider of therapies for rare endocrine disorders and related conditions, including Gvoke HypoPen (FDA-approved autoinjector for severe hypoglycemia in adults and children aged 2 years and above with diabetes), Keveyis (FDA-approved for Primary Periodic Paralysis), Recorlev (cortisol synthesis inhibitor for endogenous hypercortisolemia in adult Cushing’s), and Ogluo (glucagon injection approved in the UK/EU).
Products and services
- Recorlev: A clinical-grade cortisol synthesis inhibitor that treats endogenous hypercortisolemia in adult patients with Cushing’s syndrome when surgery is not an option or has not been curative
- Keveyis: An FDA-approved therapy that manages Primary Periodic Paralysis, including hyperkalemic and hypokalemic periodic paralysis
- Gvoke HypoPen: An FDA-approved autoinjector that treats severe hypoglycemia in adults and children aged 2 years and above with diabetes.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Strongbridge Biopharma
Jerini
HQ: Germany
Website
- Description: Provider of SPOT technology via fee-for-service project work for pharmaceutical and biotech companies, originating as a 1994 spin-off from the Medical Faculty (Charité) Humboldt University Berlin.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jerini company profile →
Aeovian Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutics for rare and age-related diseases, focused on discovering, developing, and commercializing treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aeovian Pharmaceuticals company profile →
Design Therapeutics
HQ: United States
Website
- Description: Provider of GeneTAC small-molecule therapies that modulate gene expression to treat genetic diseases caused by nucleotide repeat expansions. Programs include Friedreich ataxia (DT-216, DT-216P2 to restore FXN), Fuchs endothelial corneal dystrophy (DT-168 eye drop), Huntington's disease (reduce mutant HTT), myotonic dystrophy DM1, and research for additional genetic diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Design Therapeutics company profile →
BioCryst
HQ: United States
Website
- Description: Provider of ORLADEYO (berotralstat), an oral plasma kallikrein inhibitor for prophylaxis to prevent hereditary angioedema attacks in adults and pediatric patients 12 years and older, and RAPIVAB (peramivir injection) for acute uncomplicated influenza; also developing BCX10013 (oral Factor D inhibitor) and an oral C5 inhibitor for complement-mediated diseases, BCX17725 for Netherton syndrome, and avoralstat for diabetic macular edema.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioCryst company profile →
Manchester Pharma
HQ: United States
Website
- Description: Provider of specialty pharmaceutical capabilities focused on the identification, development, FDA approval, and commercialization of new therapeutic modalities to address the special needs of patients with ultra-rare diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Manchester Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Strongbridge Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Strongbridge Biopharma
2.2 - Growth funds investing in similar companies to Strongbridge Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Strongbridge Biopharma
4.2 - Public trading comparable groups for Strongbridge Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →